Figure 2.

DSA results: SoC (PCV13) versus PCV20, (a) costs (10% bounds), (b) QALYs (10% bounds).
Abbreviations: AC-efficacy, all-cause efficacy; DSA, deterministic sensitivity analysis; IPD, invasive pneumococcal disease; MXN, Mexican peso; PCV13, 13valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; QALY, quality-adjusted life year; SoC, standard of care.